

**CLINICAL POLICY**  
**Semaglutide****Clinical Policy: Semaglutide (Wegovy)- FEHB & Citizen's Bank Only**

Reference Number: AR.QC.CP.CPA.352

Effective Date: 01.01.26

Last Review Date: 01.26

Line of Business: QualChoice Commercial-Select  
BPLs[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

***\*This policy is only applicable to QualChoice members in BPLs 2JX62130, 2JX62131, 2JX42002, and 2JX42003. Wegovy is an excluded benefit for all other groups.***

**Description**

Semaglutide (Wegovy®) is a glucagon-like peptide-1 (GLP-1) receptor agonist.

**FDA Approved Indication(s)**

Wegovy is indicated in combination with a reduced-calorie diet and increased physical activity:

- To reduce the risk of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease (CVD) and either obesity or overweight.
- To reduce excess body weight and maintain weight reduction long term in:
  - Adult and pediatric patients aged 12 years and older with obesity;
  - Adults with overweight in the presence of at least one weight-related comorbid condition.
- For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known alcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.

Limitation(s) of use: Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of the above referenced health plans affiliated with AR QualChoice Commercial, Centene Corporation® that Wegovy is **medically necessary** when the following criteria are met:

**a. Initial Approval Criteria****A. Weight Management (must meet all):**

1. Member meets one of the following (a, b, or c):
  - a. BMI  $\geq 30$  kg/m<sup>2</sup>;
  - b. BMI  $\geq 27$  kg/m<sup>2</sup> with at least one indicator of increased cardiovascular risk (e.g., coronary artery/heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference) or other obesity-related medical condition (e.g., sleep apnea);
  - c. If age is between 12 and 17 years: BMI  $\geq 95^{\text{th}}$  percentile standardized for age and

## CLINICAL POLICY

### Semaglutide

- sex (*see Appendix D*);
2. One of the following (a or b):
    - a. Members with concurrent type 2 diabetes mellitus (T2DM): Age  $\geq$  18 years;
    - b. Members without concurrent T2DM: Age  $\geq$  12 years;
  3. For members with concurrent T2DM, both of the following (a and b):
    - a. Failure of  $\geq$  3 consecutive months each of all of the following (i, ii, iii, and iv), unless clinically significant adverse effects are experienced or all are contraindicated;\*
      - i. Ozempic® or Rybelsus®;
      - ii. Trulicity®;
      - iii. Liraglutide (generic Victoza®);
      - iv. Mounjaro;

*\*Prior authorization may be required*
    - b. If member is currently receiving a GLP-1 receptor agonist and is requesting to switch to Wegovy therapy, medical justification\* supports necessity for Wegovy;  
*\*Intolerance due to common adverse effects of the GLP-1 receptor agonist class such as gastrointestinal symptoms is not considered acceptable medical justification*
  4. Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s);
  5. Documentation of member's baseline body weight in kg;
  6. Dose does not exceed the following:
    - a. Week 1 through 4: 0.25 mg once weekly;
    - b. Week 5 through 8: 0.5 mg once weekly;
    - c. Week 9 through 12: 1 mg once weekly;
    - d. Week 13 through 16: 1.7 mg once weekly.

#### **Approval duration: 16 weeks**

#### **B. Cardiovascular Event Prevention (must meet all):**

1. Member has at least one of the following established CVD (a, b, or c):
  - a. History of myocardial infarction;
  - b. History of stroke;
  - c. Symptomatic peripheral arterial disease (PAD) (*see Appendix E*);
2. Age  $\geq$  18 years;
3. BMI  $\geq$  27 kg/m<sup>2</sup>;
4. Prescriber attestation that member is currently receiving cardiovascular standard of care management (*see Appendix E*);
5. For members with concurrent type 2 diabetes mellitus, both of the following (a and b):
  - a. Failure of  $\geq$  3 consecutive months of Rybelsus or Ozempic®, Trulicity®, and Liraglutide (generic Victoza), unless clinically significant adverse effects are experienced or all are contraindicated;\*
 

*\*Prior authorization may be required*
  - b. If member is currently receiving a GLP-1 receptor agonist and is requesting to switch to Wegovy therapy, medical justification\* supports necessity for Wegovy;  
*\*Intolerance due to common adverse effects of the GLP-1 receptor agonist class such as gastrointestinal symptoms is not considered acceptable medical justification*
6. Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s);

**CLINICAL POLICY****Semaglutide**

7. Documentation of member's baseline body weight in kg;
8. Dose does not exceed the following:
  - a. Week 1 through 4: 0.25 mg once weekly;
  - b. Week 5 through 8: 0.5 mg once weekly;
  - c. Week 9 through 12: 1 mg once weekly;
  - d. Week 13 through 16: 1.7 mg once weekly;
  - e. Week 17 and onward: 2.4 mg once weekly.

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

**C. Metabolic Dysfunction-Associated Steatohepatitis (must meet all):**

1. Diagnosis of MASH (formerly known as NASH);
2. Prescribed by or in consultation with a hepatologist or gastroenterologist;
3. Age  $\geq$  18 years;
4. MASH with stage F2 or F3 fibrosis is confirmed by one of the following (a or b):
  - a. Liver biopsy within the last 3 years;
  - b. Both of the following assessments within the last 6 months (i and ii; see Appendix G for examples):
    - i. Serum-based assessment (e.g., fibrosis-4 [FIB-4], NAFLD fibrosis score [NFS], enhanced liver fibrosis test [ELF]);
    - ii. Imaging-based assessment (e.g., vibration-controlled transient elastography [VCTE], magnetic resonance-based elastography [MRE], magnetic resonance imaging–proton density fat fraction [MRI-PDFF]);
5. For members with concurrent T2DM, member has received optimal diabetic standard of care therapy as evidenced by a trial of  $\geq$  3 consecutive months each of Ozempic<sup>®</sup> or Rybelsus, Trulicity<sup>®</sup>, Mounjaro, and Liraglutide (Victoza); unless clinically significant adverse effects are experienced or all are contraindicated;
  - \* Prior authorization may be required
  - \*\* Intolerance due to common adverse effects of the GLP-1 receptor agonist class such as gastrointestinal symptoms is not considered acceptable
6. Prescriber attestation that member is currently receiving standard of care management for concomitant related conditions, including T2DM, dyslipidemia, and hypertension;
7. Wegovy is not prescribed concurrently with Rezdifra<sup>™</sup>;
8. Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s);
9. Dose does not exceed the following:
  - a. Week 1 through 4: 0.25 mg once weekly;
  - b. Week 5 through 8: 0.5 mg once weekly;
  - c. Week 9 through 12: 1 mg once weekly;
  - d. Week 13 through 16: 1.7 mg once weekly;
  - e. Week 17 and onward: 2.4 mg once weekly.

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

**D. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL

## CLINICAL POLICY

### Semaglutide

- (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for commercial; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.33 for commercial; or
- 2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for commercial.

#### b. Continued Therapy

##### A. Weight Management (must meet all):

1. Member is currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
  - a. If this is the first renewal request, member has lost  $\geq 5\%$  of baseline body weight (adults) or baseline BMI (pediatrics);
  - b. If this is a second or subsequent renewal request, member has lost weight and/or maintained weight loss on therapy;
3. Documentation of member's current body weight in kg;
4. Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s);
5. Request meets both of the following (a and b):
  - a. Dose does not exceed 2.4 mg once weekly;
  - b. After the initial dose escalation period (*see Section V*), maintenance dose is  $\geq 1.7$  mg once weekly.

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

##### B. Cardiovascular Event Prevention (must meet all):

1. Member is currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
  - a. If this is the first renewal request, member has lost  $\geq 5\%$  of baseline body weight;
  - b. If this is a second or subsequent renewal request, member has lost weight and/or maintained weight loss on therapy;
3. Documentation of member's current body weight in kg;
4. Prescriber attestation that member is currently receiving cardiovascular standard of care management (*see Appendix E*);
5. Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s);
6. Request meets both of the following (a and b):
  - a. Dose does not exceed 2.4 mg once weekly;
  - b. After the initial dose escalation period (*see Section V*), maintenance dose is  $\geq 1.7$  mg once weekly.

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

**C. Metabolic Dysfunction-Associated Steatohepatitis (must meet all):**

1. Member is currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. After at least 12 months of therapy, member is responding positively to therapy as evidenced by, including but not limited, improvement in any of the following parameters:
  - a. Improvement in fibrosis  $\geq$  1-stage from baseline with no worsening of MASH (i.e., no worsening of hepatocellular ballooning, lobular inflammation, or steatosis);
  - b. Resolution of MASH with no worsening of fibrosis;
  - c. No increase in fibrosis stage and no worsening of MASH from baseline;
3. Prescriber attestation that member is currently receiving standard of care management for concomitant related conditions, including T2DM, dyslipidemia, and hypertension;
4. Wegovy is not prescribed concurrently with Rezdifra;
5. Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s);
6. Request meets both of the following (a and b):
  - a. Dose does not exceed 2.4 mg once weekly;
  - b. Member is able to tolerate a maintenance dose of  $\geq$  1.7 mg once weekly after at least 17 weeks of Wegovy therapy.

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

**D. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for commercial; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.33 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for commercial.

**c. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 or evidence of coverage documents.

**d. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

BMI: body mass index

CVD: cardiovascular disease

FDA: Food and Drug Administration

GLP-1: glucagon-like peptide-1

PAD: peripheral arterial disease

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications / Boxed Warnings*

- Contraindication(s): personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2), known hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy
- Boxed warning(s): risk of thyroid C-cell tumors

*Appendix D: General Information – Weight Management*

- BMI =  $703 \times [\text{weight (lbs)} / \text{height (inches)}^2]$ .
- Examples of coronary artery/heart disease include coronary artery bypass graft, angina, and history of myocardial infarction or stroke.
- The Endocrine Society practice guideline on pharmacological management of obesity states that a weight loss < 5% after 3 months of therapy indicates the weight loss medication is ineffective. In such cases, the Endocrine Society recommends that the medication be discontinued and alternative medications be considered.
- BMI cut-offs (95<sup>th</sup> percentile) for obesity by age and sex for pediatric patients aged ≥ 12 years:

Age (in years)	95 <sup>th</sup> Percentile BMI Value	
	Male	Female
12	24.2	25.2
12.5	24.7	25.7
13	25.1	26.3
13.5	25.6	26.8
14	26.0	27.2
14.5	26.4	27.7
15	26.8	28.1
15.5	27.2	28.5
16	27.5	28.9
16.5	27.9	29.3
17	28.2	29.6
17.5	28.6	30.0

*Appendix E: General Information – Cardiovascular Event Prevention*

- In the SELECT trial, symptomatic PAD was defined as intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease.
- Cardiovascular standard of care management:
  - Dyslipidemia management may include a statin, ezetimibe, fibrate, omega-3 fatty acids, or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
  - Hypertension management may include an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), calcium channel blocker, or a thiazide diuretic.
  - Non-acute management of myocardial infarction may include beta-blockers, long-term dual antiplatelet therapy with aspirin and a P2Y<sub>12</sub> receptor blocker, statins (high-intensity), ACE inhibitors, aldosterone antagonist, and/or nitroglycerin.
  - Secondary prevention therapies for ischemic stroke may include antithrombotic therapy, antihypertensive therapy, and/or statins.
  - Secondary prevention therapies for PAD may include antiplatelet therapy, antithrombotic therapy, lipid-lowering therapy (e.g., statins), antihypertensive therapy, and/or glycemic control therapy (e.g., metformin, sulfonylurea, GLP-1 receptor agonists, sodium-glucose cotransporter-2 [SGLT2] inhibitors, etc.).

**e. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Weight management, CV event prevention	<p><u>Adults</u></p> <p>SC once weekly following dose escalation schedule:</p> <ul style="list-style-type: none"> <li>• Week 1 through 4: 0.25 mg</li> <li>• Week 5 through 8: 0.5 mg</li> <li>• Week 9 through 12: 1 mg</li> <li>• Week 13 through 16: 1.7 mg</li> <li>• Week 17 and onward*: 1.7 mg or 2.4 mg</li> </ul> <p>If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.</p> <p>The maintenance dosage in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.</p> <p><u>Pediatric patients aged ≥ 12 years old</u></p> <p>SC once weekly following dose escalation schedule:</p> <ul style="list-style-type: none"> <li>• Week 1 through 4: 0.25 mg</li> <li>• Week 5 through 8: 0.5 mg</li> <li>• Week 9 through 12: 1 mg</li> <li>• Week 13 through 16: 1.7 mg</li> <li>• Week 17 and onward*: 2.4 mg</li> </ul>	2.4 mg/week



Indication	Dosing Regimen	Maximum Dose
	<p>If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.</p> <p>If patients do not tolerate the 2.4 mg once-weekly maintenance dose, the maintenance dose may be reduced to 1.7 mg once weekly. Discontinue Wegovy if the patient cannot tolerate the 1.7 mg dose.</p> <p><i>* 0.25 mg, 0.5 mg, and 1 mg once-weekly dosages are initiation and escalation dosages and are not approved as maintenance dosages</i></p>	

**f. Product Availability**

Pre-filled, single-dose pens: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg

**g. References**

1. Wegovy Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.; March 2024. Available at: [www.wegovy.com](http://www.wegovy.com). Accessed May 10, 2024.

Weight Management

2. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity [published online ahead of print, 2023 Jan 9]. *Pediatrics*. 2023;e2022060640.
3. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. *N Engl J Med*. 2022;387(24):2245-2257.
4. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014; 129 (suppl 2): S102–S138.
5. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015; 100(2): 42-362.

Cardiovascular Event Prevention

6. ClinicalTrials.Gov Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT). Available at: <https://classic.clinicaltrials.gov/ct2/show/NCT03574597>. Accessed May 10, 2024
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. December 2023; 389(24): 2221-2232.
8. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. *American Heart Journal* 2022;229:80-80.
9. Lingvay I, Brown-Frandsen K, Colhoun HM et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. *Obesity* 2023;31:111-122.



10. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2021;144(22):e336-e367.
11. Kleindorfer DO, Chaturvedi S, Cockcroft KM, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke 2021;52(7):e364-e467.
12. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2017;135(12):e686-e725.

### **Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<b>HCPCS Codes</b>	<b>Description</b>
C9399	Unclassified drugs or biologicals
J3490	Unclassified drugs

<b>Reviews, Revisions, and Approvals</b>	<b>Date</b>	<b>P&amp;T Approval Date</b>
Policy reviewed & adapted for AR QualChoice specific use. Removed requirement for weight-management program, updated off-label & no coverage criteria policies referenced.	02/27/25	
Added preferred product Mounjaro to list of required T&F	10/14/25	
Updated based on new FDA approval of Rybelsus for MACE risk reduction	11/12/25	
Added BPL to list of covered groups	12/19/25	
Updated policy to include redirections to formulary alternative GLP-1 agonists for weight management, MASH, and cardiovascular event protection with concurrent T2DM, updated reference number, updated age limits for weight management indication to mirror corporate policy. updated Victoza redirections to Liraglutide per formulary. Updated MASH continued therapy step 1 to remove continuity of care regulations verbiage. Formatting changes	1/2/26	

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

## CLINICAL POLICY

### Semaglutide

approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered

## CLINICAL POLICY

### Semaglutide

trademarks exclusively owned by Centene Corporation.

